CB-5083 is primarily investigated for its potential in cancer therapy. It functions as a selective inhibitor of p97, a protein critical for the ubiquitin-proteasome system, which is responsible for degrading damaged or misfolded proteins in cells. By inhibiting p97, CB-5083 disrupts this system, leading to the accumulation of toxic proteins and ultimately causing cancer cell death. This mechanism makes it a promising candidate for treating various cancers, particularly those resistant to conventional therapies. Research is ongoing to evaluate its efficacy in preclinical and clinical settings, with a focus on its ability to target tumors while minimizing effects on healthy cells. Additionally, CB-5083 is being studied for its potential in combination therapies to enhance the effectiveness of other anticancer agents.